Abstract:e17565 Background: BRCA1 and BRCA2 are tumour suppressor genes, involved in the homologous repair of double-stranded DNA breaks, located at 17q21.31 and 13q13.1, respectively. Germline BRCA1/2 mutations are identified in 13-15% of ovarian cancers (OC), while an additional 5-7% of ovarian cancers harbor somatic BRCA1/2 mutations among foreign populations. To determine the landscape of germline and somatic pathogenic BRCA1 and BRCA2 alterations in Chinese patients with ovarian cancer tested by next‐generation sequencing (NGS), with the aim of defining the best strategy to be implemented in future routine testing. Methods: 472 normal-paired samples from Chinese patients with ovarian cancers were analyzed using hybridization capture-based next generation sequencing. Somatic and germline mutations were identified including 500 genes associated with tumor development. Sequencing data were analyzed to call tumor specific single nucleotide variants (SNV), small insertions and deletions (InDels), copy number alterations (CNA) and gene fusions and rearrangements. Results: Overall, 472 ovarian cancer patients underwent somatic and/or germline NGS analysis, the BRCA1 and BRCA2 genes sequenced in this study covers all targeted coding exons and exon-intron boundaries. Among these patients, 54/472 (11.4%) patients carried BRCA( BRCA1/2) mutations. Inside, there were 43/472 (9.1%) patients occurred somatic BRCA mutations, 62.8% (27/43) of variants were in BRCA1 and 37.2% (16/43) were in BRCA2. Furthermore, 3 cases carried BRCA1 and BRCA2 somatic co-mutation, of which only 1 showed BRCA1/ BRCA2 copy number losses. In 54 OC patients who carried BRCA mutations, 10 patients occured copy number alterations, of which 6 patients showed BRCA1 copy number losses, 4 patients showed BRCA2 copy number losses, and 1 patient showed BRCA2 copy number gains. Germline BRCA variant was detected in 18/472 (3.8%) patients, 66.7% (12/18) of variants were in BRCA1 and 33.3% (6/18) were in BRCA2. Of the 12 BRCA1 germline mutations, 11 were pathogenic heterozygous mutations (c.2679_2682del; c.2101_2102del; c.5085_5086insT; c.1660G > T; c.4810C > T; c.1504_1508del; c.1465G > T; c.1480C > T; c.2110_2111del; c.4185+1G > A; c.81-2A > G), one was likely pathogenic heterozygous mutation (c.5216A > G). Of the 6 BRCA 2 germline mutations, four were pathogenic heterozygous mutations (c.5722_5723del; c.5291C > G; c.5164_5165del; c.3109C > T), one was likely pathogenic heterozygous mutation (c.869_870del), and one was uncertain significance heterozygous mutation (c.7976+3A > G). Conclusions: This study revealed the molecular features of BRCA1 and BRCA2 in Chinese ovarian cancer patients, which could help to identify therapeutic targets and personalize therapy management, leading to improved patient outcomes as predictive biomarkers or platinum-based therapy.

Large-scale copy number alterations are enriched for synthetic viability in BRCA1/BRCA2 tumors

Copy number alterations: a catastrophic orchestration of the breast cancer genome

Copy-number and Gene Dependency Analysis Reveals Partial Copy Loss of Wild-Type SF3B1 As a Novel Cancer Vulnerability.

The landscape of somatic copy-number alteration across human cancers

High-Resolution Genomic And Expression Analyses Of Copy Number Alterations In Breast Tumors

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

53BP1 Loss Rescues Embryonic Lethality but Not Genomic Instability of BRCA1 Total Knockout Mice

Abstract 1512: Evolution of large copy number variants in breast cancer through genetic network rewiring

Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer

Supplementary Tables S1-S4 from the BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Characterization of BRCA1-deficient Premalignant Tissues and Cancers Identifies Plekha5 As a Tumor Metastasis Suppressor

Signatures of copy number alterations in human cancer

Deletions Rate-Limit Breast and Ovarian Cancer Initiation

Abstract 4369: Genome-wide Copy Number Dependency Analysis Identifies Partial Copy Loss of SF3B1 As a Novel Cancer Vulnerability

A Synergetic Effect of BARD1 Mutations on Tumorigenesis

Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors

Luminal breast epithelial cells from wildtype and mutation carriers harbor copy number alterations commonly associated with breast cancer

Mutation of the Brca1 Sq-Cluster Results in Aberrant Mitosis, Reduced Homologous Recombination, and A Compensatory Increase in Non-Homologous End Joining

The landscape of BRCA1 and BRCA2 alterations in Chinese ovarian cancer patients.

BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality

Single Allele Loss-of-function Mutations Select and Sculpt Conditional Cooperative Networks in Breast Cancer